Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Operating Income (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Operating Income data on record, last reported at -$345.8 million in Q1 2026.

  • On a quarterly basis, Operating Income fell 91.3% to -$345.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.1 billion, a 71.22% decrease, with the full-year FY2025 number at -$923.7 million, down 62.18% from a year prior.
  • Operating Income reached -$345.8 million in Q1 2026 per PCVX's latest filing, down from -$274.3 million in the prior quarter.
  • Over the last five years, Operating Income for PCVX hit a ceiling of -$39.2 million in Q1 2022 and a floor of -$345.8 million in Q1 2026.
  • A 5-year average of -$149.4 million and a median of -$139.9 million in 2024 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: tumbled 190.07% in 2022, then grew 17.55% in 2024.
  • Tracing PCVX's Operating Income over 5 years: stood at -$86.6 million in 2022, then tumbled by 127.18% to -$196.7 million in 2023, then increased by 17.55% to -$162.2 million in 2024, then tumbled by 69.13% to -$274.3 million in 2025, then dropped by 26.09% to -$345.8 million in 2026.
  • Business Quant data shows Operating Income for PCVX at -$345.8 million in Q1 2026, -$274.3 million in Q4 2025, and -$242.4 million in Q3 2025.